Q-omics provides the consensus-scored C2orf49 profile across patient tissues and cancer cell-line models. C2orf49 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, C2orf49 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, C2orf49 protein abundance shows 28,556 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, THCA, and LSCC as cancer lineages where C2orf49 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C2orf49 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C2orf49 survival associations across molecular data types. C2orf49 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C2orf49 RNA expression–survival associations across cancer types. High C2orf49 expression shows unfavorable associations in KIRP, LIHC, ACC, UVM and MESO, but favorable associations in SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRP as the clearest survival context for C2orf49 RNA expression.
This table summarizes C2orf49 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for C2orf49. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C2orf49 shows lower tumor expression in THCA and BRCA and higher tumor expression in HNSC, LIHC, COAD and CHOL. The THCA box plot shows higher C2orf49 RNA expression in normal versus tumor tissue (log2 FC = −0.752, t-test p < 0.001).
This table shows molecular features associated with C2orf49 in patient tissues and cancer cell lines. In patient samples, C2orf49 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, C2orf49 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
